Board of directors

Anker Lundemose, MD PhD

Chair

CEO at Mission Therapeutics focused on selectively targeting deubiquitylating enzymes to treat diseases of high unmet need.

Roderick Verhelst, PhD

Bioqube Ventures

Principal at Bioqube Ventures focusing on sourcing, financing and developing innovative therapeutic assets and technologies.

Jeroen Bakker, PhD

Novo Seeds

Principal at Novo Holdings and part of the Novo Seeds team focusing early-stage financing and development of strong and competitive companies.

Nick Stub Laursen, PhD

Head of Discovery & Co-founder

Nick has extensive experience in antibody characterization and has worked within the field of complement research for more than 15 years.

Mikkel Wandahl Pedersen, PhD

CEO & CSO

Seasoned R&D executive and scientific leader with over two decades of experience in antibody development from immuno-oncology and autoimmune disease drug discovery programs.

Eva Van Overmeire, PhD

Senior Investment Manager

Senior Investment Manager at Korys focusing on investments in companies developing science-based solutions that prevent or treat diseases.

Janine Schuurman, PhD

Antibody enthusiast and molecular Immunologist

Formerly served as SVP Antibody Research and Technology at Genmab. Pioneered IgG4 biology and IgG1-complement interactions leading to groundbreaking insights in antibody biology. Co-inventor of numerous therapeutic antibodies, including FDA-approved RYBREVANT® (amivantamab) and EPKINLY® (epcoritamab). Also co-inventor of the bispecific antibody platform DuoBody® and effector function-enhanced HexaBody® and HexElect® technologies.

Advisors

Gavin Thurston, PhD

Biotech scientist in oncology and vascular biology

Dr. Thurston has spent most of his career focused on cancer biology and developing biotherapeutics. He was at Regeneron Pharmaceuticals for 22 years, leading cancer discovery efforts and most recently as Senior Vice President of Oncology Research. Dr. Thurston has authored over 150 scientific publications and is an inventor on over 50 US patents and ongoing patent applications. His efforts at Regeneron led to the successful clinical development of LIBTAYO® and ongoing late-stage clinical testing of 7 other antibodies and bispecific antibodies.

Frank Landolt, PhD

Patent attorney and transactional lawyer

Previously member of the management team at Ablynx, responsible for IP strategy, building a strong patent estate and involved in negotiating various partnerships with leading pharma companies. Ablynx was acquired by Sanofi in 2018 for $4.8B.

Gregers R. Andersen, PhD

Complementologist and structural biologist

Gregers has more than 25 years of experience within the complement system and structural biology and has served as an advisor for several pharmaceutical companies with complement targeting drugs in their pipeline. Gregers is currently Professor at the department of Molecular Biology and Genetics at Aarhus University where he is leading his own research group.

Paul W.H.I. Parren, PhD

Professor of Molecular Immunology

Prof. dr. Paul W.H.I. Parren is a pioneer in translating antibody knowledge into innovative biologic drugs for treating human diseases. From 2002-2017, he led research and preclinical development at Genmab, and from 2018-2023, he headed R&D at LAVA Therapeutics NV, bringing it to a clinical-stage, NASDAQ-listed, biotechnology company. His work contributed to nine FDA and EMA-approved therapeutic antibodies, including four therapeutics from the DuoBody bispecific antibody platform. His scientific publications have >42,000 citations and he holds >360 issued patents in US, EU and JP. He is a tenured Professor of Molecular Immunology at the LUMC in Leiden, chairs the Board of Directors of the non-profit trade organization The Antibody Society. He recently cofounded Gyes BV (2022), Moirea BV and Olethros BV (2024), an ecosystem of start-up companies pioneering the development of highly selective multifunctional antibody therapeutics.